JP2007224041A5 - - Google Patents

Download PDF

Info

Publication number
JP2007224041A5
JP2007224041A5 JP2007109439A JP2007109439A JP2007224041A5 JP 2007224041 A5 JP2007224041 A5 JP 2007224041A5 JP 2007109439 A JP2007109439 A JP 2007109439A JP 2007109439 A JP2007109439 A JP 2007109439A JP 2007224041 A5 JP2007224041 A5 JP 2007224041A5
Authority
JP
Japan
Prior art keywords
oxcarbazepine
microns
agent according
fasting
median diameter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007109439A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007224041A (ja
Filing date
Publication date
Priority claimed from GBGB9925962.4A external-priority patent/GB9925962D0/en
Application filed filed Critical
Publication of JP2007224041A publication Critical patent/JP2007224041A/ja
Publication of JP2007224041A5 publication Critical patent/JP2007224041A5/ja
Pending legal-status Critical Current

Links

JP2007109439A 1999-11-02 2007-04-18 医薬組成物 Pending JP2007224041A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9925962.4A GB9925962D0 (en) 1999-11-02 1999-11-02 Organic compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2001534388A Division JP2003514780A (ja) 1999-11-02 2000-10-31 医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012172912A Division JP2012211202A (ja) 1999-11-02 2012-08-03 医薬組成物

Publications (2)

Publication Number Publication Date
JP2007224041A JP2007224041A (ja) 2007-09-06
JP2007224041A5 true JP2007224041A5 (enExample) 2010-11-25

Family

ID=10863836

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2001534388A Withdrawn JP2003514780A (ja) 1999-11-02 2000-10-31 医薬組成物
JP2007109439A Pending JP2007224041A (ja) 1999-11-02 2007-04-18 医薬組成物
JP2012172912A Pending JP2012211202A (ja) 1999-11-02 2012-08-03 医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2001534388A Withdrawn JP2003514780A (ja) 1999-11-02 2000-10-31 医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012172912A Pending JP2012211202A (ja) 1999-11-02 2012-08-03 医薬組成物

Country Status (25)

Country Link
US (3) US20060079502A1 (enExample)
EP (1) EP1242091B1 (enExample)
JP (3) JP2003514780A (enExample)
KR (1) KR100493836B1 (enExample)
CN (1) CN1407894A (enExample)
AT (1) ATE401892T1 (enExample)
AU (1) AU777705B2 (enExample)
BR (1) BR0015188A (enExample)
CA (1) CA2388609C (enExample)
CZ (1) CZ302847B6 (enExample)
DE (1) DE60039629D1 (enExample)
ES (1) ES2311001T3 (enExample)
GB (1) GB9925962D0 (enExample)
HK (1) HK1050839B (enExample)
HU (1) HU227685B1 (enExample)
IL (3) IL149147A0 (enExample)
MX (1) MXPA02004389A (enExample)
NO (1) NO330947B1 (enExample)
NZ (1) NZ518378A (enExample)
PL (1) PL200273B1 (enExample)
RU (1) RU2330666C2 (enExample)
SK (1) SK287479B6 (enExample)
TR (1) TR200200951T2 (enExample)
WO (1) WO2001032183A2 (enExample)
ZA (1) ZA200203394B (enExample)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022056A1 (en) 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
MXPA04011801A (es) * 2002-05-31 2005-09-12 Desitin Arzneimittel Gmbh Composicion farmaceutica que contiene oxcarbazepina con liberacion controlada de la substancia activa.
EP1528927A1 (en) * 2002-08-06 2005-05-11 Novartis AG Use of carboxamides for the treatment of tinnitus
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
BRPI0414112A (pt) * 2003-09-03 2006-10-31 Novartis Ag uso de oxcarbazepina para o tratamento de dor neuropática diabética e a melhora do sono
AR048672A1 (es) * 2004-03-22 2006-05-17 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
UA86802C2 (ru) * 2004-04-13 2009-05-25 Бёрингер Ингельхайм Интернациональ Гмбх Комбинация симетикона и бисакодила для предрасположенных к запору пациентов, которые страдают от ощущения вздутия живота
WO2006046105A1 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Oxcarbazepine dosage forms
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2007008576A2 (en) * 2005-07-08 2007-01-18 Taro Pharmaceuticals U.S.A., Inc. Oxcarbazepine formulation
WO2007029093A2 (en) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Pharmaceutical dosage forms of oxcarbazepine
EP2029118A2 (en) * 2006-01-31 2009-03-04 Teva Pharmaceutical Industries, Inc. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
EP1815849A1 (en) * 2006-01-31 2007-08-08 Teva Pharmaceutical Industries Ltd Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
ES2396051T3 (es) * 2006-04-26 2013-02-18 Supernus Pharmaceuticals, Inc. Preparaciones de liberación controlada de oxcarbazepina que tienen perfil de liberación sigmoidal
US20080138403A1 (en) * 2006-12-08 2008-06-12 Sun Pharmaceutical Industries Ltd. Pharmaceutical dosage forms of oxcarbazepine
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
CA2681628C (en) 2007-03-16 2016-10-18 Concert Pharmaceuticals, Inc. Inhibitors of cholesterol ester transfer protein
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
US7528131B2 (en) * 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
US20090042842A1 (en) 2007-04-25 2009-02-12 Concert Pharmaceuticals, Inc. Analogues of cilostazol
MX341177B (es) 2007-05-01 2016-08-10 Concert Pharmaceuticals Inc Compuestos de morfina.
PT2357183E (pt) 2007-05-01 2015-09-28 Concert Pharmaceuticals Inc Compostos de morfinano
CA2685924A1 (en) * 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Naphthyl(ethyl)acetamides
EP2522667B1 (en) * 2007-05-01 2014-08-20 Concert Pharmaceuticals Inc. Morphinan compounds
PL2003120T3 (pl) 2007-06-12 2010-04-30 Concert Pharmaceuticals Inc Pochodne azapeptydu jako inhibitory proteazy HIV
EP2212298B1 (en) * 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
MX2010009300A (es) 2008-02-29 2010-11-05 Concert Pharmaceuticals Inc Derivados de xantina substituidos.
US20110160253A1 (en) * 2008-05-28 2011-06-30 Harbeson Scott L Deuterated tizanidine
US20100221221A1 (en) * 2008-08-12 2010-09-02 Concert Pharmaceuticals Inc. N-phenyl-2-pyrimidineamine derivatives
WO2010033801A1 (en) 2008-09-19 2010-03-25 Concert Pharmaceuticals Inc. Morphinan compounds
WO2010062692A1 (en) 2008-10-30 2010-06-03 Concert Pharmaceuticals Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
EP2364151A1 (en) 2008-10-30 2011-09-14 Concert Pharmaceuticals Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
KR20110093832A (ko) 2008-11-04 2011-08-18 앵커 테라퓨틱스, 인코포레이티드 Ｃｘｃｒ4 수용체 화합물
US20110313004A1 (en) 2008-12-04 2011-12-22 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
BRPI1009199A2 (pt) 2009-03-17 2016-03-08 Concert Pharmaceuticals Inc compostos de pirazinoisoquinolina
WO2010138889A1 (en) 2009-05-28 2010-12-02 Concert Pharmaceuticals, Inc. Peptides for the treatment of hcv infections
EP2454259A1 (en) 2009-06-23 2012-05-23 Concert Pharmaceuticals Inc. Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
WO2011047315A1 (en) 2009-10-15 2011-04-21 Concert Pharmaceuticals, Inc. Subsitituted benzimidazoles
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
WO2011060216A1 (en) 2009-11-12 2011-05-19 Concert Pharmaceuticals Inc. Substituted azaindoles
WO2011103457A1 (en) 2010-02-18 2011-08-25 Concert Pharmaceuticals Inc. Pyrimidine derivatives
US9155795B2 (en) 2010-02-26 2015-10-13 Anchor Therapeutics, Inc. CXCR4 receptor compounds
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US8513434B2 (en) 2010-03-02 2013-08-20 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
WO2012037060A1 (en) 2010-09-13 2012-03-22 Concert Pharmaceuticals Inc. Substituted azaindoles
WO2012065028A2 (en) 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
US8447329B2 (en) 2011-02-08 2013-05-21 Longsand Limited Method for spatially-accurate location of a device using audio-visual information
EP2678337A1 (en) 2011-02-25 2014-01-01 Concert Pharmaceuticals Inc. 2-amino-naphthyridine derivatives
WO2012129381A1 (en) 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
US20140213553A1 (en) 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
WO2012154728A1 (en) 2011-05-10 2012-11-15 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
ES2758028T3 (es) 2011-05-18 2020-05-04 Vertex Pharmaceuticals Europe Ltd Derivados deuterados de ivacaftor
US20140296263A1 (en) 2011-07-19 2014-10-02 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
CA2860740A1 (en) 2012-01-09 2013-07-18 Anchor Therapeutics, Inc. Apj receptor compounds
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
IN2014DN08443A (enExample) 2012-04-13 2015-05-08 Concert Pharmaceuticals Inc
US9249093B2 (en) 2012-04-20 2016-02-02 Concert Pharmaceuticals, Inc. Deuterated rigosertib
EA201492287A1 (ru) 2012-06-15 2015-07-30 Консерт Фармасьютикалс, Инк. Дейтерированные производные руксолитиниба
CA2908929C (en) 2012-07-12 2021-01-26 Concert Pharmaceuticals, Inc. Deuterated idebenone
MX361499B (es) 2012-08-17 2018-12-06 Concert Pharmaceuticals Inc Baricitinib deuterado.
WO2014078842A1 (en) 2012-11-19 2014-05-22 Concert Pharmaceuticals, Inc. Deuterated cftr potentiators
MX2015008187A (es) 2012-12-20 2016-02-05 Concert Pharmaceuticals Inc Inhibidores de alk deuterados.
EP2938343B1 (en) 2012-12-21 2018-09-12 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
AU2014235462C1 (en) 2013-03-15 2018-11-01 Concert Pharmaceuticals, Inc. Deuterated palbociclib
EP2968268B1 (en) 2013-03-15 2020-07-29 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
WO2015010045A1 (en) 2013-07-18 2015-01-22 Anchor Therapeutics, Inc. Apj receptor compounds
US9676790B2 (en) 2013-08-30 2017-06-13 Concert Pharmaceuticals, Inc. Substituted thienotriazolodiazapines
WO2015063670A1 (en) * 2013-10-30 2015-05-07 Wockhardt Limited Solid oral modified-release composition comprising oxcarbazepine or a pharmaceutically acceptable salt thereof
EP3105232B1 (en) 2014-02-10 2019-08-28 Concert Pharmaceuticals Inc. Substituted triazolobenzodiazepines
CA2981791A1 (en) 2014-04-18 2015-10-22 Concert Pharmaceuticals, Inc. Methods of treating hyperglycemia
WO2015179772A1 (en) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Deuterated phenylquinazolinone and phenylisoquinolinone compounds
MA39999A (fr) 2014-06-06 2015-12-10 Res Triangle Inst Agonistes du récepteur de l'apeline (apj) et leurs utilisations
US10301273B2 (en) 2014-08-07 2019-05-28 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
WO2016073545A1 (en) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
WO2016089814A1 (en) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Deuterated analogues of daclatasvir
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
WO2016144830A1 (en) 2015-03-06 2016-09-15 Concert Pharmaceuticals, Inc. Deuterated emricasan
AU2016243171B2 (en) 2015-03-31 2020-10-08 Concert Pharmaceuticals, Inc. Deuterated VX-661
US10683305B2 (en) 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
WO2017020005A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Morphinan compounds for use in treating agitation
WO2017020002A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
MX388470B (es) 2015-09-21 2025-03-20 Vertex Pharmaceuticals Europe Ltd Administración de potenciadores de regulador de la conductancia transmembrana de fibrosis quística (cftr) deuterados.
EP3377179B1 (en) 2015-11-19 2021-04-07 Concert Pharmaceuticals Inc. Deuterated epi-743
EP3386976A1 (en) 2015-12-09 2018-10-17 Research Triangle Institute, International Improved apelin receptor (apj) agonists and uses thereof
WO2017147003A1 (en) 2016-02-26 2017-08-31 Novobiotic Pharmaceuticals, Llc Novel macrocyclic antibiotics and uses thereof
US10561659B2 (en) 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
EP3825307B1 (en) 2016-07-04 2022-08-03 Avanir Pharmaceuticals, Inc. Methods for the synthesis of deuterated dextromethorphan
WO2018026833A1 (en) 2016-08-01 2018-02-08 The Brigham And Women's Hospital, Inc. Particles for delivery of proteins and peptides
EP3589659B1 (en) 2017-02-28 2025-04-09 Mayo Foundation for Medical Education and Research Combinations for use in the treatment of cancer
US11278025B2 (en) 2017-05-17 2022-03-22 The General Hospital Corporation Antibiotic compounds
PH12019502544B1 (en) 2017-05-19 2023-07-26 Superb Wisdom Ltd Derivatives of resiquimod
IL322463A (en) 2017-11-22 2025-09-01 Sun Pharmaceutical Ind Inc Deuterated d-serine analogs and their uses
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
CN114144229A (zh) 2019-04-10 2022-03-04 梅约医学教育与研究基金会 心血管功能障碍的性别依赖性治疗方法和材料
CN115003335A (zh) * 2019-11-08 2022-09-02 林德拉治疗公司 用于施用活性剂的胃驻留系统
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
CA3184471A1 (en) 2020-05-27 2021-12-02 The Penn State Research Foundation Antibacterial compounds
EP4236956A1 (en) 2020-10-28 2023-09-06 Sun Pharmaceutical Industries, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
WO2023018904A1 (en) 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
CA3228509A1 (en) 2021-08-12 2023-02-16 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
AU2023265574A1 (en) 2022-05-04 2024-12-12 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US20020022056A1 (en) * 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets

Similar Documents

Publication Publication Date Title
JP2007224041A5 (enExample)
Prakash et al. Preparation and characterization of lamivudine microcapsules using various cellulose polymers
Zhang et al. Coaxial electrospray formulations for improving oral absorption of a poorly water-soluble drug
RU2002113752A (ru) Фармацевтические композиции
JP2008280352A (ja) 溶解性または経口吸収性の改善された組成物
Agubata et al. Formulation, characterization and anti-malarial activity of homolipid-based artemether microparticles
JP2017517551A5 (enExample)
EA031255B1 (ru) Состав с отсроченным высвобождением, содержащий гранулы цистеамина, и способы его получения и применения
Taki et al. Preparation of polymer-blended quinine nanocomposite particles by spray drying and assessment of their instrumental bitterness-masking effect using a taste sensor
Abouelatta et al. Floating lipid beads for the improvement of bioavailability of poorly soluble basic drugs: In-vitro optimization and in-vivo performance in humans
US20160038550A1 (en) Methods and compositions for treating conditions associated with memory loss
Riekes et al. Evaluation of oral carvedilol microparticles prepared by simple emulsion technique using poly (3-hydroxybutyrate-co-3-hydroxyvalerate) and polycaprolactone as polymers
Patel et al. Application of mathematical models in drug release kinetics of Lagerstroemia speciosa extract-phospholipid complex
Penteado et al. Chitosan-coated poly (є-caprolactone) nanocapsules for mucoadhesive applications of perillyl alcohol
Fung et al. Preparation, in-vitro and in-vivo characterisation of CoQ10 microparticles: electrospraying-enhanced bioavailability
JP2015120758A5 (enExample)
Ruhidas et al. Evaluation of gum katira as a model sustained release adjuvant in the preparation of etodolac loaded microsphere
Tezel et al. Preparation and in vitro characterization of memantine HCl loaded PLGA nanoparticles for Alzheimer's disease
WO2007053904A1 (en) Process to control particle size
Mumuni et al. Development and Evaluation of Artemether-loaded Microspheres Delivery System for Oral Application in Malaria Treatment: doi. org/10.26538/tjnpr/v5i11. 23
Shivakumar et al. Design and evaluation of controlled onset extended release multiparticulate systems for chronotherapeutic delivery of ketoprofen
Malayer et al. Genotoxicity of noscapine nanosuspension on DU145 human prostate cancer (spheroid cell model)
Mahajan et al. Polymer based nanoparticles for BCS class II drugs-“A mini Review”
Parmar et al. Sustained release floating microspheres of acyclovir: formulation, optimization, characterization and in vitro evaluation
WO2013109316A1 (en) Enteric-coated ht-2157 compositions and methods of their use